Omeprazol Viatris (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Viatris, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat gastro‑reflux disease and related conditions in adults and children. GNH USA supplies Omeprazol Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omeprazol Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazol Viatris is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders: - Gastro‑esophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the condition. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates. - NSA‑ID‑induced gastropathy: helps prevent ulcer formation in patients requiring long‑term NSAID therapy.

Omeprazol Viatris is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually self‑limiting. - Nausea: occasional and transient. - Abdominal pain: mild discomfort. - Flatulence: increased intestinal gas. - Constipation: occasional bowel habit change.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk. - Acute interstitial nephritis: renal inflammation. - Hypomagnesemia: low serum magnesium levels. - Stevens‑Johnson syndrome: severe skin reaction. - Hepatotoxicity: elevated liver enzymes. - Fracture risk: decreased bone mineral density with long‑term use.

Before starting Omeprazol Viatris, consider the following safety points: - Assess renal function: dose adjustment may be needed in severe impairment. - Review liver status: use with caution in hepatic disease. - Evaluate need for long‑term therapy: prolonged use is linked to nutrient malabsorption. - Monitor for infections: increased risk of gastrointestinal infections. - Pregnancy and lactation: weigh benefits against potential risks. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Omeprazol Viatris can affect the plasma concentrations of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular events. - Atazanavir: decreased antiviral exposure, may compromise HIV treatment. - Dasatinib: lower drug levels, reduced efficacy in chronic myeloid leukemia.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, monitor coagulation parameters. - Phenytoin: decreased phenytoin levels, watch for seizure control. - Digoxin: modest rise in serum digoxin, assess cardiac status. - Methotrexate: increased exposure, especially at high doses.